Previous Article | Next Article 
Journal of Virology, May 2001, p. 4048-4055, Vol. 75, No. 9
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.9.4048-4055.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Regulation of Viral Intermediate Gene Expression by
the Vaccinia Virus B1 Protein Kinase
Gerald R.
Kovacs,1,*
Nikos
Vasilakis,1 and
Bernard
Moss2
Department of Viral Vaccine Research,
Wyeth-Lederle Vaccines, Pearl River, New York
10965,1 and Laboratory of Viral
Diseases, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, Bethesda, Maryland
208922
Received 2 November 2000/Accepted 2 February 2001
 |
ABSTRACT |
The B1 gene of vaccinia virus encodes a serine/threonine protein
kinase that is expressed early after infection. Under nonpermissive conditions, temperature-sensitive mutants (ts2 and
ts25) that map to B1 fail to efficiently replicate viral
DNA. Our goal was to extend studies on the function of B1 by
determining if the kinase is required for intermediate or late gene
expression, two events that ordinarily depend on viral DNA replication.
First, we established that early viral gene expression occurred at the nonpermissive temperature. By using a transfection procedure that circumvents the viral DNA replication requirement, we found that reporter genes regulated by an intermediate promoter were transcribed only under conditions permissive for expression of active B1. To assay
late gene expression, the T7 RNA polymerase gene was inserted into the
genome of ts25 to form ts25/T7. A DNA
replication-independent late gene transcription system was established
by cotransfecting plasmids containing T7 promoter-driven late gene
transcription factors and a late promoter reporter gene into
ts25/T7-infected cells. Late genes, unlike intermediate
genes, were expressed at the nonpermissive temperature. Last, we showed
that overexpression of B1 stimulated intermediate but inhibited late
gene expression in cells infected with wild-type virus.
 |
INTRODUCTION |
DNA viruses have evolved regulatory
systems in which early and late stage genes are transcribed from
parental and replicated genomes, respectively. Poxviruses have added
some unique features to this general strategy. The enzymes needed for
transcription of early genes are expressed late in infection, packaged
within progeny virions, and activated when the core is released into the cytoplasm following infection (26). In addition, there
are two postreplicative stages of poxvirus gene expression,
intermediate and late, rather than just one. All of the viral factors
required for DNA replication and expression of intermediate genes are
products of early genes, whereas the viral factors needed for late gene expression are products of both early and intermediate genes. Thus, the
poxvirus life cycle occurs in a temporally ordered sequence: early gene
expression
viral DNA replication
intermediate gene expression
late gene expression. The extent to which vaccinia virus proteins
interact with one another and/or with cellular proteins to link viral
DNA replication with intermediate and late gene expression is not understood.
Studies on the regulation of intracellular processes involved in
eukaryotic nucleic acid metabolism have pointed to protein phosphorylation as playing a key role. Poxviruses have acquired analogs
of a number of host cell genes to maintain their autonomy from the
cell, including two serine/threonine protein kinases (B1 and F10) and a
dual-specificity protein phosphatase (H1). The F10 kinase
(22) and H1 phosphatase (15) are expressed late in infection, are incorporated into virions, and play major roles
in virion morphogenesis (11, 24, 38). Interestingly, the
H1 phosphatase has been implicated in early gene transcription (24). Mutant virus particles devoid of H1 phosphatase were
unable to transcribe early genes either in vivo or in vitro. This
finding led us to investigate the role that phosphorylation might play in the transcription of the other gene classes. The B1 kinase is
expressed exclusively early in infection; it localizes to viral replication factories and appears to be a minor component of the virion
(3, 23, 34). The B1 kinase associates with
(25) and phosphorylates (5, 6) viral late
gene transcription factor 4 (VLTF-4; viral protein H5) and two
ribosomal proteins in vitro. Temperature-sensitive (ts)
vaccinia virus mutants (ts2 and ts25) that map to
the B1 gene have a defect in viral DNA replication (9, 28)
and consequently would not be expected to express intermediate or late
genes. To analyze intermediate and late gene expression, we used a
transfection-based assay that mimics the requirement for viral DNA
replication (18, 37). Our results show that B1 is
essential for the transcription of viral intermediate but not late genes.
 |
MATERIALS AND METHODS |
Cells and viruses.
African green monkey kidney (BS-C-1) and
murine fibroblast (L929) cells were maintained in minimal essential
medium (MEM; Life Technologies) supplemented with 10% fetal bovine
serum (Life Technologies). The ts mutants ts2 and
ts25 were obtained from Richard Condit (8, 9)
and grown and titered on BS-C-1 cells. For virological assays,
incubations were at permissive (32°C) and nonpermissive (39.5°C)
temperatures. Cytosine
-D-arabinosidase (AraC; Sigma)
was used at 44 µg/ml to block viral DNA replication in certain experiments.
Plasmid constructions and reporter gene assays.
Three
reporter genes were used in this study: p30/300, pG8R-CAT, and p11KCAT.
The construction of p30/300, a plasmid that contains 300 bp of DNA
upstream of the vaccinia virus intermediate G8R gene open reading frame
(ORF) fused to the lacZ ORF, has been described elsewhere
(1). pG8R-CAT was constructed by digesting p30/300 with
BamHI and HindIII, completely removing the lacZ
ORF, and subsequently inserting a compatible fragment containing the chloramphenicol acetyltransferase (CAT) ORF in its place. The resultant
plasmid (pG8R-CAT) retains the same 300 bp of G8R upstream sequences as
p30/300. A late gene reporter plasmid, p11K-CAT, was constructed in two
steps. First, pG8R-CAT was digested with BamHI, and a
synthetic DNA duplex containing 65 bp of sequence upstream of the 11K
ORF was inserted so that only the upstream BamHI site was
regenerated. Second, the resultant plasmid was digested with
BamHI and SalI to completely remove the G8R
regulatory sequences. The final plasmid (p11K-CAT) contains the CAT ORF
under the regulation of the 11K late promoter. A T7 promoter-B1
expression plasmid (pT7-B1) was constructed by PCR amplification of the
wild-type B1 ORF from vaccinia virus strain WR DNA and insertion of
this fragment into the EcoRI and BamHI sites of
pSG5 (14). The same vector expressing a nonsense mutant
(pT7
B1) of the B1 gene was engineered by inserting a synthetic
adapter (5'-AATTCTAGCTAGCTAG-3') into the MfeI site in the
B1R ORF. Expression of pT7-
B1 would result in a truncated B1 gene
product terminating at the 11th amino acid.
Transfections were carried out with Qiagen column-purified DNAs using
the DOTAP transfection reagent (Boehringer Mannheim) and OptiMEM (Life
Technologies). Typically, 5 µg of covalently closed, circular,
supercoiled DNA was mixed with 15 µl of DOTAP per transfection. In
transfection-infection experiments, cells (approximately 2 × 106 to 3 × 106 per dish) were transfected
3 h prior to infection. The temperature of transfections was kept
constant at 37°C. Viral inocula were prepared by trypsinizing stocks
at 30°C for 30 min. Extracts were prepared by washing cells in
ice-cold phosphate-buffered saline twice and freeze-thawing three times
in 500 µl of 1× reporter lysis buffer (Promega). Typically, 1 to 10 µl of cell extract was analyzed to remain within the linear range of
enzyme assays.
-Galactosidase assays were conducted as specified by
the manufacturer (Promega) and quantitated using an EL 312E
Bio-Kinetics Reader (Bio-Tek Instruments). CAT assays were done using a
fluorescently labeled chloramphenicol substrate (FAST CAT yellow;
Molecular Probes) (17, 39). Reaction products were
separated by thin-layer chromatography, analyzed on a FluorImager
(Molecular Dynamics), and quantitated with ImageQuant software
(Molecular Dynamics).
Protein analyses.
Radioimmunoprecipitations were conducted
by labeling cells for 30 min with 50 µCi of
[35S]methionine (Amersham) per ml in MEM lacking
methionine. Extracts were prepared by washing cells with ice-cold
phosphate-buffered saline, suspending the cells in 1×
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl [pH
7.2], 150 mM NaCl, 1% NP-40), and clarifying the lysate by
microcentrifugation for 5 min. Subsequently, anti-vaccinia virus
antibody (BioGenesis) was added at 1:500 to the clarified supernatant,
and mixtures were rocked for 4 to 6 h at 4°C. Immune complexes
were captured with 50 µl of 20% protein A-Sepharose CL-4B
(Pharmacia), and the beads were washed three times with 1× RIPA buffer
containing 0.1% sodium dodecyl sulfate (SDS). Immune complexes were
boiled in SDS-polyacrylamide gel electrophoresis (PAGE) loading buffer
(0.05 M Tris, 4% SDS, 4%
-mercaptoethanol, 10% glycerol, 0.1%
bromophenol blue) for 5 min and microcentrifuged for 30 s. The
solubilized proteins were then resolved on 5 to 20% polyacrylamide
gels (21). Gels were dried and analyzed by autoradiography.
Western blotting was conducted by transferring proteins onto
polyvinylidene difluoride membranes (Millipore), incubating in
blocking
buffer (0.89 M Tris, 0.89 M borate, 0.02 M EDTA, 1% NP-40,
1% nonfat
dry milk), and probing with either anti-vaccinia virus
(1:1,000;
BioGenesis), anti-

-galactosidase (1:500; 5'-3', Inc.),
anti-TrpE-B1
(1:500), or anti-T7 polymerase (1:1,500) in blocking
buffer. Immune
complexes were detected with an alkaline phosphatase-conjugated
goat
anti-rabbit immunoglobulin G antibody (1:1,500; Life Technologies)
and
the Western Blue reagent
(Promega).
RNase protection assay.
Total RNA was purified from
approximately 4 × 106 to 5 × 106
cells using the TRlzol total RNA isolation reagent (Life Technologies), treated with DNase I (5 U for 15 min at 37°C; Ambion), precipitated with LiCl, and resuspended in H2O. A T7 promoter-containing
template for riboprobe synthesis was made by PCR using two
oligonucleotides (5'-GTCAAAAATTGTAGAACGAC-3' and
5'-TAATACGACTCACTATAGGGGTACATTGAGCAAC-3'; T7
promoter is underlined) and pG8R-CAT as the DNA template. The 161-nucleotide (nt) antisense riboprobe derived from T7 RNA polymerase transcription of this template should protect the first 96 nt of the
G8RCAT mRNA. Approximately, 600 pg of uniformly radiolabeled riboprobe
was mixed with 10 µg of total RNA and assayed using an RPA II kit
essentially as described by the manufacturer (Ambion). Protected
fragments were separated on 5% polyacrylamide-1× Tris-borate EDTA
TBE-8 M urea gels and visualized by autoradiography.
 |
RESULTS |
Synthesis of viral early proteins under nonpermissive
conditions.
Vaccinia virus ts B1 mutants exhibit a
defect in viral DNA replication at the nonpermissive temperature
(8, 9, 28) and consequently should not express
intermediate or late gene products. To confirm this phenotype and
establish whether viral early protein synthesis was preserved, cells
were infected with wild-type virus (WR) or ts25 at 32°C
(permissive for ts25) or 39.5°C (nonpermissive for
ts25). L929 cells were used because the mutants exhibit a
stringent ts phenotype in them (28). The infected cells were metabolically labeled with
[35S]methionine at various times after infection. Lysates
were prepared and incubated with a polyclonal antiserum that was raised
by repeatedly injecting a rabbit with live vaccinia virus Lister strain
and therefore recognizes early as well as late viral proteins. Some cells were treated with AraC to block viral DNA synthesis in order to
have a bona fide early protein pattern for comparison. At 32°C in the
absence of AraC, we detected viral early proteins in 3 h and
intermediate or late proteins at subsequent times, regardless of
whether the cells were infected with WR or ts25 (Fig.
1A). In the presence of AraC, the 3-h
early pattern persisted and similar patterns were obtained with WR and
ts25 at 32°C (Fig. 1A). Virtually identical results were
also obtained with the two viruses at 39.5°C in the presence of AraC,
indicating that ts25 is fully competent to express early
proteins at the nonpermissive temperature. In the absence of AraC,
however, only early viral proteins were made by cells infected with
ts25 at 39.5°C, whereas a typical early/late pattern was
made by WR under these conditions. We also demonstrated by Western
blotting that the B1 gene, which is regulated by an early promoter, is
expressed under nonpermissive conditions (Fig. 2B). Although the results were fully
compatible with a primary defect in DNA replication, they did not
preclude the possibility of additional specific defects in intermediate
or late gene expression.

View larger version (90K):
[in this window]
[in a new window]
|
FIG. 1.
SDS-PAGE analysis of viral proteins synthesized in
ts25-infected cells. L929 cells were infected with either
the WR or ts25 strain of vaccinia virus and incubated at the
permissive (A) or nonpermissive (B) temperature in the presence or
absence of AraC. Cells were labeled with [35S]methionine
for 30 min at the indicated times (hours postinfection [hpi]).
Lysates were prepared, immunoprecipitated with anti-vaccinia virus
antiserum, and analyzed by SDS-PAGE. Masses of protein standards in
kilodaltons are indicated to the left. U, uninfected; MW, molecular
weight standards.
|
|

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 2.
Temperature dependence of intermediate gene expression
in ts25-infected L929 cells. (A) L929 cells were transfected
with p30/300 and subsequently infected with WR or ts25 at 32 or 39.5°C. Extracts were prepared at 0, 3, 6, 9, and 18 h
postinfection (hpi) and assayed for -galactosidase activity.
Absorbances (optical densities) at 495 nm (OD495) were
plotted on the ordinate. (B) The lysates prepared at 18 h after
infection were also assayed by Western blotting using antiserum
specific for -galactosidase (Bgal) or the B1R protein. The masses of
protein standards are indicated in kilodaltons on the left. Arrows
denote the location of the proteins of interest. M, mock infected.
|
|
Specific inhibition of intermediate gene expression under
nonpermissive conditions.
To determine if B1 had an additional
role in intermediate gene expression, we needed to bypass the
requirement for viral DNA synthesis which is blocked in
ts25-infected cells at the nonpermissive temperature.
Previous studies had shown that genes regulated by intermediate
promoters are expressed from transfected plasmids, which functionally
mimic replicated DNA when DNA synthesis is inhibited (37).
When L929 cells were transfected with a plasmid (p30/300) containing
the lacZ gene regulated by an intermediate (G8R) promoter
(1) and then infected with WR, synthesis of
-galactosidase was detected between 8 and 18 h at both 32 and 39.5°C (Fig. 2A). At 32°C,
-galactosidase activity was even
higher in cells infected with ts25 than in cells infected
with WR (Fig. 2A). However, at 39.5°C, little or no activity was
detected in cells infected with ts25 (Fig. 2A).
Corresponding results were obtained by Western blotting with antibody
to
-galactosidase (Fig. 2B). Furthermore, results similar to these
were obtained using another B1 mutant virus (ts2) (data not shown).
Although previous reports demonstrated the expression of intermediate
genes from transfected plasmids in the absence of DNA
replication, we
needed to confirm that this occurs using L929
cells. In addition, we
decided to carry out similar studies with
BS-C-1 cells, which are used
more commonly than L929 cells for
studies with vaccinia virus. Plasmid
p30/300, containing an intermediate
gene promoter fused to the
lacZ gene, was transfected into cells
that were then
infected with WR or
ts25. As in L929 cells,

-galactosidase
synthesis was higher in BS-C-1 cells infected with
ts25 than with
WR at 32°C but was nearly undetectable at
39.5°C (Fig.
3B and
C). We carried out
parallel experiments with L929 and BS-C-1 cells
in which AraC was added
to the medium at the start of infection.
In this way, there would be a
DNA replication block under all
conditions and with both wild-type and
mutant viruses. We found
that reporter gene expression occurred in the
presence of AraC
at 32°C (Fig.
3A and C), although the levels were
reduced in cells
infected with either WR or
ts25. At
39.5°C, however, reporter
gene expression was specifically blocked in
cells infected with
ts25 (Fig.
3A and C). We concluded,
therefore, that there was
a
ts defect in intermediate gene
expression independent of effects
on viral DNA replication.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 3.
The block in intermediate gene expression is independent
of DNA replication. BS-C-1 or L929 cells were transfected with p30/300
and subsequently infected with 5 PFU of WR or ts25 per cell
in the presence of absence of AraC at the indicated temperature.
Lysates were prepared at 24 h after infection and assayed for
-galactosidase activity (optical density at 495 nm
[OD495]). Experiments were done in triplicate, and
standard deviations are indicated by the shaded areas at the tops of
the bars. M, mock infected.
|
|
Inhibition of intermediate gene expression occurred at the
transcriptional level.
Because the synthesis of early proteins
appeared to be unaffected by the ts mutation of B1, i.e.,
there was no global effect on translation, we suspected that the
inhibition of intermediate gene expression occurred at the
transcriptional level. To investigate this, we selected CAT as the
reporter gene because its mRNA is only 600 nt, compared to 3,000 nt for
lacZ mRNA. We considered that if the defect were in RNA
elongation or degradation, then synthesis of CAT might be less severely
affected than that of
-galactosidase. Such experiments, however,
indicated that CAT synthesis was severely inhibited at 39.5°C in
ts25-infected L929 cells (Fig.
4A).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 4.
Intermediate gene expression is inhibited at the level
of transcription. (A) BS-C-1 cells were transfected with pG8R-CAT and
then mock infected at 39°C or infected with 0.5 PFU of WR or
ts25 per cell at 32 or 39.5°C. Lysates were prepared at
24 h after infection and assayed for CAT activity, expressed as
percent acetylation. Experiments were done in triplicate, and standard
deviations are denoted over the bars. (B) BS-C-1 cells were transfected
with pG8R-CAT and mock infected or infected with WR or ts25
at 32 or 39.5°C as indicated above. Approximately 18 h later,
total RNA was purified and analyzed by an RNase protection assay.
Reaction products were separated by denaturing electrophoresis. The
arrow denotes the size of the protected G8R-CAT RNA fragment. Sizes of
RNA markers (MWM; RNA Century Marker; Ambion) in nucleotides are shown
at the left.
|
|
An RNase protection assay was performed to determine more directly
whether the block in intermediate gene expression occurred
at the level
of transcription. RNA was purified from BS-C-1 cells
that had been
transfected with pG8R-CAT and infected with either
ts25 or
WR. We used BS-C-1 instead of L929 cells in this experiment
because of
the better integrity of RNAs isolated from the former
cell type. The
riboprobe was designed to quantify steady-state
levels of CAT mRNA and
also to determine if the mRNAs initiated
at the correct position
relative to the G8R promoter. A discrete
RNA product of predicted size
was detected in cells infected with
WR or
ts25 at 32°C or
with WR at 39°C (Fig.
4B). Little or no
G8RCAT mRNA was detected in
cells infected with
ts25 at the nonpermissive
temperature,
suggesting that in the absence of B1, intermediate
mRNAs are either not
transcribed or have very short half-lives
(Fig.
4B).
Construction of a ts25 mutant that expresses
bacteriophage T7 RNA polymerase.
We decided to make recombinant
virus ts25T7, which retains the ts25 mutation in
the B1 gene and expresses the T7 RNA polymerase gene regulated by an
early promoter. This virus would allow us to further evaluate the block
in intermediate transcription by determining (i) whether a reporter
gene regulated by a T7 promoter would be expressed at 39.5°C, (ii) if
coexpression of the wild-type B1 gene would reverse the ts
phenotype, and (iii) whether expression of late genes was affected at
the nonpermissive temperature. Since the assays would be done at
39.5°C and in the presence of AraC, we first needed to determine
whether sufficient T7 RNA polymerase would be expressed by
ts25T7 under these conditions. A Western blot analysis (Fig.
5A) indicated that at least as much T7
RNA polymerase was synthesized by ts25T7 as by VTF7.3, a
well-characterized vaccinia virus WR recombinant containing the T7 RNA
polymerase gene (13). At least two cross-reactive species
of lower molecular weight were detected; because they are not present
in the wild-type virus-infected lysate, we posit that they are cleavage
and/or breakdown products of T7 polymerase. As expected, since the T7 gene is under an early/late promoter, blocking late transcription with
AraC resulted in less synthesis of full-length as well as truncated T7
proteins. We also needed to establish that ts25T7 could
function as a T7 RNA polymerase expression vector in transient assays
and retained the ts defect. Cells were transfected with either pG8RCAT or pT7CAT and infected with ts25T7 or VTF7.3.
The transfection experiment shown in Fig. 5B indicated that
ts25T7 allowed the expression of CAT regulated by an
intermediate promoter at 32°C but not at 39.5°C. In contrast,
vTF7.3 allowed the expression of CAT at either temperature (Fig. 5B).
Significantly, the CAT gene regulated by a T7 promoter was expressed to
similar levels at either temperature by ts25T7 or VTF7.3
(Fig. 5C). Thus, the block in transcription was specific for an
intermediate gene promoter.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 5.
Expression of reporter genes in cells infected with
ts25T7. (A) L929 cells were infected with ts25T7
at the indicated temperatures in the presence or absence of AraC.
Lysates were prepared at 24 h after infection and analyzed by
Western blotting using an anti-T7 RNA polymerase antibody. A 97.4-kDa
protein standard (MWM) and the expected position of T7 RNA polymerase
(denoted by the arrow) are indicated on the left and right,
respectively. (B and C) L929 cells were transfected with pG8R-CAT or
pT7-CAT and infected with either ts25T7 or VTF7.3 at the
indicated temperatures. Extracts were prepared at 18 h after infection
and assayed for CAT activity (expressed as percent acetylation).
|
|
The next series of experiments were carried out to determine whether
the
ts25 defect could be overcome by coexpression of
a
wild-type copy of the B1 gene. Plasmid pT7-B1, containing the
B1 ORF
adjacent to a T7 promoter, was constructed and shown to
program the
synthesis of a 34-kDa protein that bound to anti-B1
serum in a coupled
reticulocyte transcription-translation system
(data not shown). Cells
were then transfected with pG8R-CAT and
pT7-B1 (containing an intact B1
ORF under T7 promoter control)
or pT7-

B1 (containing a truncated B1
ORF under T7 promoter control)
and then infected with
ts25T7
or vTF7.3. Transfection of pT7-B1
enhanced intermediate gene expression
in cells infected with vTF7.3
at 32 or 39.5°C, whereas transfection
with pT7-

B1 did not (Fig.
6). In
contrast, intermediate gene expression was enhanced by
transfection of
pT7-B1 in cells that were infected with
ts25T7
at 32°C but
not at 39.5°C (Fig.
6). Apparently,
trans expression
of B1
enhanced intermediate gene expression in the presence of
limiting
amounts of active B1 kinase but not in the presence of
mutated B1
kinase at the nonpermissive temperature. Either the
mutated B1 protein
had a dominant negative effect or active kinase
was not expressed early
enough from the transfected plasmid to
prevent an irreversible
inhibition of intermediate gene transcription.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 6.
Expression of B1 in trans enhances
intermediate gene expression under permissive but not nonpermissive
conditions. L929 cells were transfected with either pG8R-CAT alone or
pG8R-CAT and pT7-B1 or pT7- B1. After transfection, cells were
infected with ts25T7 or VTF7.3 at the indicated
temperatures. Lysates were prepared at 24 h after infection and
assayed for CAT activity (expressed as percent acetylation). This
experiment was conducted five separate times, and standard deviations
are denoted over the bars.
|
|
Analysis of late gene expression.
To extend our analysis to
the role of the B1 kinase in late gene expression, we adapted a
transfection protocol devised by Keck et al. (18). Late
promoters, like intermediate promoters, can regulate transcription of a
reporter gene in a transfected plasmid during an AraC block. An
additional requirement, however, is that the genes encoding VLTF-1, -2, and -3 (viral genes A1, A2, and G8, respectively) must be cotransfected
with the late promoter reporter plasmid. However, because A1, A2, and
G8 are of the intermediate gene class, they would be silent during
nonpermissive infection of cells with ts25 or
ts25T7, and consequently the late transcription factors
would not be made. To overcome this problem, we transfected plasmids
containing the A1, A2, and G8 ORFs under the control of T7 promoters
(18). Late transcription was monitored by cotransfecting a
reporter plasmid (p11K-CAT) containing the CAT gene under the control
of the viral 11K late gene promoter. The cells were subsequently
infected with ts25T7 to provide the T7 RNA polymerase to
drive the expression of the three VLTF genes. Under these conditions,
CAT synthesis occurred either at 32 or 39.5°C in the presence of
AraC, indicating that B1 was not specifically required for
transcription of late genes (Fig. 7).
Control experiments verified that there was low CAT expression in the
absence of transfected VLTF plasmids when cells were infected with
ts25T7 at either temperature in the presence of AraC or at
39.5°C in the absence of AraC (Fig. 7).

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 7.
B1 is not required for late gene expression. L929 cells
were transfected with p11K-CAT alone or with three plasmids (pT7-A1L,
pT7-A2L, and pT7-G8R) that express VLTFs regulated by T7 promoters. The
transfected cells were infected with ts25T7 at 32 or
39.5°C to provide T7 RNA polymerase. CAT activity was assayed at
24 h after infection and normalized to the value obtained for
sample 1.
|
|
Knowing that B1 was not essential for late gene expression, we
determined the effects of overexpression. Cells were cotransfected
with
pT7-B1 or pT7

-B1 and p11K-CAT and subsequently infected
with VTF7.3
containing a wild-type B1 gene and T7 RNA polymerase
(Fig.
8). The results indicate that
trans expression of B1 inhibited
late gene expression by
nearly 85%.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 8.
Expression of B1 in trans inhibits late gene
expression. L929 cells were transfected with p11K-CAT and pT7-B1 or
pT7- B1 and subsequently infected with VTF7.3 at 37°C. CAT activity
(expressed as percent acetylation) was assayed at 24 h after
infection. Standard deviations are shown above the bars.
|
|
 |
DISCUSSION |
Several studies demonstrated that the B1 kinase plays an important
role in viral DNA replication temperature (8, 9, 28).
However, in some cell lines this effect seemed insufficient to entirely
account for the reduction in virus titer and plaque formation. For
example, at 39.5°C, ts25 directed the synthesis of up to
60% of control levels of DNA but only 15% of control levels of viable
progeny and no distinct plaques in BS-C-40 cells (28).
This is in contrast to other studies conducted on ts
vaccinia virus mutants, where a decrease in viral DNA synthesis
resulted in a concomitant reduction of comparable magnitude in viral
titers (33). Therefore, we considered that B1 might have
another role downstream of viral DNA replication. In this report, we
provide evidence that intermediate gene transcription is blocked at the nonpermissive temperature and, unlike the defect in DNA replication, is
similarly restricted in mouse and monkey cells.
We first showed that early gene expression was unaltered in cells
infected with ts25 at the nonpermissive temperature, whereas late gene expression was completely blocked. Because this defect would
result from inhibition of viral DNA synthesis, we relied on
transfection experiments to specifically analyze the expression of
intermediate and late genes at the nonpermissive temperature. Although
a reporter gene regulated by an intermediate promoter was expressed in
cells infected with wild-type vaccinia virus even in the presence of a
potent inhibitor of DNA synthesis, expression did not occur at 39.5°C
in cells infected with ts25. This result provided evidence
that B1 was required for intermediate gene expression independent of
any effect on DNA replication. Furthermore, the block occurred at the
level of transcription. By constructing a recombinant virus that
contained the ts25 defect and a T7 RNA polymerase gene, we
demonstrated that a reporter gene regulated by a T7 promoter was
expressed under nonpermissive conditions, ruling out a global defect in
plasmid-based transcription. Moreover, by cotransfecting the
intermediate genes encoding late transcription factors under T7
promoters, we could demonstrate that B1 was not required for
transcription of a reporter plasmid with a late promoter. Transfection
experiments further showed that overexpression of wild-type B1
stimulated intermediate gene expression from 1.5- to 3.5-fold but
severely inhibited late gene expression in cells expressing functional
B1. Failed attempts to reverse the block in intermediate transcription
by expression of wild-type B1 at 39.5°C suggested that the
ts B1 protein may be trans-dominant to the
wild-type protein. Alternatively, if the timing of B1 synthesis is
crucial, then expression from the T7 promoter, which depends on prior
synthesis of T7 RNA polymerase, may occur too late.
We are uncertain as to how the B1 kinase is involved in intermediate
gene expression. In vivo studies have shown that intermediate genes are
transiently expressed from 1 to 4 h after infection (2). Biochemical analyses have indicated that at least six proteins (viral intermediate transcription factors [VITFs]) are required for transcription; these include the multisubunit viral RNA
polymerase (35), viral capping enzyme (16,
36), VITF-1 (viral protein E4 [29]), VITF-3 (a
complex of the viral A8 and A23 proteins [31]), and an
unidentified cellular factor termed VITF-2 (30). An in
vitro transcription system consisting solely of recombinant proteins
has not been derived; thus, the possibility of additional factors or
posttranslational modification of known ones remains. For example, the
B1 kinase may be associated with a partially purified component of the
transcription system or may have phosphorylated a viral or cellular
factor prior to purification. Another possibility is that the viral H5
protein is involved in intermediate transcription. This protein,
identified as VLTF-4 (19), is the only VLTF synthesized
prior to DNA replication (20). The fact that H5 is
phosphorylated in vitro by the B1 protein kinase (5) and
is underphosphorylated by a B1 ts mutant at the
nonpermissive temperature (4) makes H5 an attractive candidate for further investigation.
Additional studies indicate that the H5 protein interacts with viral
proteins encoded by the A18 and G2 genes, which are involved in
transcription elongation (7), and the A20 gene
(25), involved in DNA replication (12). The
situation is even more complex because a recent report of
charge-to-alanine mutagenesis of the H5 ORF produced a ts
mutant that has a block in viral morphogenesis with no apparent defect
in either viral DNA or protein synthesis (10). Whether the
B1 kinase is directly involved in this additional role of the H5
protein is unknown.
The B1 gene is conserved among many but not all poxviruses. Molluscum
contagiosum virus encodes homologs of the F10 protein kinase and the H1
phosphatase but does not contain a B1 homolog (32). One
explanation for its absence from the molluscum contagiosum virus genome
is that it may be compensated by a host cell protein kinase. In this
regard, there are two human putative serine/threonine protein kinases,
VRK1 and VRK2, with a high degree of sequence similarity to the B1
kinase (27).
Taking into consideration the complexity of the cellular pathways that
are regulated by protein phosphorylation and dephosphorylation, it is
not surprising that the B1 protein kinase has multiple effects on the
vaccinia virus life cycle. Clearly, more work is required to identify
all of the viral and cellular factors that are regulated by the B1
protein kinase.
 |
ACKNOWLEDGMENTS |
We thank Richard Condit for ts2, ts25, and
helpful discussions, Paula Traktman for sharing unpublished results and
ideas, Ehud Katz for advice on virological assays, Cristina Cassetti and Stephen Udem for reviewing the manuscript, Steve Broyles for anti-TrpE-B1 antiserum, Sally Lee for anti-T7 polymerase antiserum, and
Norman Cooper for invaluable assistance with cell culture.
G.R.K. was supported by a National Research Council fellowship while
working at the NIH.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Wyeth-Lederle
Vaccines, Department of Viral Vaccine Research, Pearl River, NY 10965. Phone: (845) 732-5974. Fax: (845) 732-4941. E-mail:
KOVACSG{at}WAR.WYETH.COM.
This work is dedicated to the memory of Roskey Jennings, whose
character was an inspiration to the many people who passed through the
Laboratory of Viral Diseases.
 |
REFERENCES |
| 1.
|
Baldick, C. J.,
J. G. Keck, and B. Moss.
1992.
Mutational analysis of the core, spacer, and initiator regions of vaccinia virus intermediate class promoters.
J. Virol.
66:4710-4719[Abstract/Free Full Text].
|
| 2.
|
Baldick, C. J., Jr., and B. Moss.
1993.
Characterization and temporal regulation of mRNAs encoded by vaccinia virus intermediate stage genes.
J. Virol.
67:3515-3527[Abstract/Free Full Text].
|
| 3.
|
Banham, A., and G. L. Smith.
1992.
Vaccinia virus gene B1R encodes a 34-kDa serine/threonine protein kinase that localizes in cytoplasmic factories and is packaged into virions.
Virology
191:803-812[CrossRef][Medline].
|
| 4.
|
Beaud, G., and R. Beaud.
2000.
Temperature-dependent phosphorylation state of the H5R protein sythesized at the early stage of infection in cells infected with vaccinia virus ts mutants of the B1R and F10L protein kinases.
Intervirology
43:67-70[CrossRef][Medline].
|
| 5.
|
Beaud, G.,
R. Beaud, and D. P. Leader.
1995.
Vaccinia virus gene H5R encodes a protein that is phosphorylated by the multisubstrate vaccinia virus B1R protein kinase.
J. Virol.
69:1819-1826[Abstract].
|
| 6.
|
Beaud, G.,
A. Sharif,
A. Topamass, and D. P. Leader.
1994.
Ribosomal-protein S2/SA kinase purified from HeLa cells infected with vaccinia virus corresponds to the B1R protein-kinase and phosphorylates in-vitro the viral ssDNA-bindng protein.
J. Gen. Virol.
75:283-293[Abstract/Free Full Text].
|
| 7.
|
Black, E. P.,
N. Moussatche, and R. C. Condit.
1998.
Characterization of the interactions among vaccinia virus transcription factors G2R, A18R, and H5R.
Virology
245:313-322[CrossRef][Medline].
|
| 8.
|
Condit, R. C., and A. Motyczka.
1981.
Isolation and preliminary characterization of temperature-sensitive mutants of vaccinia virus.
Virology
113:224-241[CrossRef][Medline].
|
| 9.
|
Condit, R. C.,
A. Motyczka, and G. Spizz.
1983.
Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus.
Virology
128:429-443[CrossRef][Medline].
|
| 10.
|
DeMasi, J., and P. Traktman.
2000.
Clustered charge-to-alanine mutagenesis of the vaccinia virus H5 gene: isolation of a dominant, temperature-sensitive mutant with a profound defect in morphogenesis.
J. Virol.
74:2393-2405[Abstract/Free Full Text].
|
| 11.
|
Derrien, M.,
A. Punjabi,
M. Khanna,
O. Grubisha, and P. Traktman.
1999.
Tyrosine phosphorylation of A17 during vaccinia virus infection: involvement of the H1 phosphatase and the F10 kinase.
J. Virol.
73:7287-7296[Abstract/Free Full Text].
|
| 12.
|
Du, S., and P. Traktman.
1996.
Vaccinia virus DNA replication: two hundred base pairs of telomeric sequence confer optimal replication efficiency on minichromosome templates.
Proc. Natl. Aca. Sci. USA
93:9693-9698[Abstract/Free Full Text].
|
| 13.
|
Fuerst, T. R.,
E. G. Niles,
F. W. Studier, and B. Moss.
1986.
Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.
Proc. Natl. Acad. Sci. USA
83:8122-8126[Abstract/Free Full Text].
|
| 14.
|
Green, S.,
I. Issemann, and E. Sheer.
1988.
A versatile in vivo and in vitro eukaryotic expression vector for protein engineering.
Nucleic Acids Res.
16:369[Free Full Text].
|
| 15.
|
Guan, K.,
S. S. Broyles, and J. E. Dixon.
1991.
A Tyr/Ser protein phosphatase encoded by vaccinia virus.
Nature
350:359-362[CrossRef][Medline].
|
| 16.
|
Harris, N.,
R. Rosales, and B. Moss.
1993.
Transcription initiation factor activity of vaccinia virus capping enzyme is independent of mRNA guanylylation.
Proc. Natl. Acad. Sci. USA
90:2860-2864[Abstract/Free Full Text].
|
| 17.
|
Hruby, D. E., and E. M. Wilson.
1992.
Use of fluorescent chloramphenicol derivative as a substrate for chloramphenicol acetyltransferase assays.
Methods Enzymol.
216:369-376[Medline].
|
| 18.
|
Keck, J. G.,
C. J. Baldick, and B. Moss.
1990.
Role of DNA replication in vaccinia virus gene expression: a naked template is required for transcription of three late transactivator genes.
Cell
61:801-809[CrossRef][Medline].
|
| 19.
|
Kovacs, G. R., and B. Moss.
1996.
The vaccinia virus H5R gene encodes viral late gene transcription factor 4: purification, cloning, and overexpression.
J. Virol.
70:6796-6802[Abstract/Free Full Text].
|
| 20.
|
Kovacs, G. R.,
R. Rosales,
J. G. Keck, and B. Moss.
1994.
Modulation of the cascade model for regulation of vaccinia virus gene expression: purification of a prereplicative, late-stage-specific transcription factor.
J. Virol.
68:3443-3447[Abstract/Free Full Text].
|
| 21.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature (London)
227:680-685[CrossRef][Medline].
|
| 22.
|
Lin, S., and S. S. Broyles.
1994.
Vaccinia protein kinase 2: a second essential serine/threonine protein kinase encoded by vaccinia virus.
Proc. Natl. Acad. Sci. USA
91:7653-7657[Abstract/Free Full Text].
|
| 23.
|
Lin, S.,
W. Chen, and S. S. Broyles.
1992.
The vaccinia virus B1R gene product is a serine/threonine protein kinase.
J. Virol.
66:2717-2723[Abstract/Free Full Text].
|
| 24.
|
Liu, K.,
B. Lemon, and P. Traktman.
1995.
The dual-specificity phosphatase encoded by vaccinia virus, VH1, is essential for viral transcription in vivo and in vitro.
J. Virol.
69:7823-7834[Abstract].
|
| 25.
|
McCraith, S.,
T. Holtzman,
B. Moss, and S. Fields.
2000.
Genome-wide analysis of vaccinia virus protein-protein interactions.
Proc. Natl. Acad. Sci. USA
97:4879-4884[Abstract/Free Full Text].
|
| 26.
|
Moss, B.
1996.
Poxviridae: the viruses and their replication, p. 2637-2671.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 27.
|
Nezu, J.,
A. Oku,
M. H. Jones, and M. Shimane.
1997.
Identification of two novel human putative serine/threonine kinases, VRK1 and VRK2, with structural similarity to vaccinia virus B1R kinase.
Genomics
45:327-331[CrossRef][Medline].
|
| 28.
|
Rempel, R. E.,
M. K. Anderson,
E. Evans, and P. Traktman.
1990.
Temperature-sensitive vaccinia virus mutants identify a gene with an essential role in viral replication.
J. Virol.
64:574-583[Abstract/Free Full Text].
|
| 29.
|
Rosales, R.,
N. Harris,
B.-Y. Ahn, and B. Moss.
1994.
Purification and identification of a vaccinia virus-encoded intermediate stage promoter-specific transcription factor that has homology to eukaryotic transcription factor SII (TFIIS) and an additional role as a viral RNA polymerase subunit.
J. Biol. Chem.
269:14260-14267[Abstract/Free Full Text].
|
| 30.
|
Rosales, R.,
G. Sutter, and B. Moss.
1994.
A cellular factor is required for transcription of vaccinia viral intermediate stage genes.
Proc. Natl. Acad. Sci. USA
91:3794-3798[Abstract/Free Full Text].
|
| 31.
|
Sanz, P., and B. Moss.
1999.
Identification of a transcription factor, encoded by two vaccinia virus early genes, that regulates the intermediate stage of viral gene expression.
Proc. Natl. Acad. Sci. USA
96:2692-2697[Abstract/Free Full Text].
|
| 32.
|
Senkevich, T. G.,
E. V. Koonin,
J. Bugert,
G. Darai, and B. Moss.
1997.
The genome of molluscum contagiosum virus: analysis and comparison with other poxiviruses.
Virology
233:19-42[CrossRef][Medline].
|
| 33.
|
Taddie, J. A., and P. Traktman.
1991.
Genetic characterization of the vaccinia virus DNA polymerase: identification of point mutations conferring altered drug sensitivities and reduced fidelity.
J. Virol.
65:869-879[Abstract/Free Full Text].
|
| 34.
|
Traktman, P.,
M. K. Anderson, and R. E. Rempel.
1989.
Vaccinia virus encodes an essential gene with strong homology to protein kinases.
J. Biol. Chem.
264:21458-21461[Abstract/Free Full Text].
|
| 35.
|
Vos, J. C.,
M. Sasker, and H. G. Stunnenberg.
1991.
Promoter melting by a stage-specific vaccinia virus transcription factor is independent of the presence of RNA polymerase.
Cell
65:105-114[CrossRef][Medline].
|
| 36.
|
Vos, J. C.,
M. Sasker, and H. G. Stunnenberg.
1991.
Vaccinia virus capping enzyme is a transcription initiation factor.
EMBO J.
10:2553-2558[Medline].
|
| 37.
|
Vos, J. C., and H. G. Stunnenberg.
1988.
Derepression of a novel class of vaccinia virus genes upon DNA replication.
EMBO J.
7:3487-3492[Medline].
|
| 38.
|
Wang, S., and S. Shuman.
1995.
Vaccinia virus morphogenesis is blocked by temperature-sensitive mutations in the F10 gene, which encodes protein kinase 2.
J. Virol.
69:6376-6388[Abstract].
|
| 39.
|
Young, S. L.,
L. Barbera,
A. H. Kaynard,
R. P. Haugland,
H. C. Kang,
M. Brinkley, and M. H. Melner.
1991.
A nonradioactive assay for transfected chloramphenicol acetyltransferase activity using fluorescent substrates.
Anal. Biochem.
197:401-407[CrossRef][Medline].
|
Journal of Virology, May 2001, p. 4048-4055, Vol. 75, No. 9
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.9.4048-4055.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kang, T.-H., Park, D.-Y., Kim, W., Kim, K.-T.
(2008). VRK1 phosphorylates CREB and mediates CCND1 expression. J. Cell Sci.
121: 3035-3041
[Abstract]
[Full Text]
-
Li, L.-Y., Liu, M.-Y., Shih, H.-M., Tsai, C.-H., Chen, J.-Y.
(2006). Human cellular protein VRK2 interacts specifically with Epstein-Barr virus BHRF1, a homologue of Bcl-2, and enhances cell survival.. J. Gen. Virol.
87: 2869-2878
[Abstract]
[Full Text]
-
Resch, W., Weisberg, A. S., Moss, B.
(2005). Vaccinia Virus Nonstructural Protein Encoded by the A11R Gene Is Required for Formation of the Virion Membrane. J. Virol.
79: 6598-6609
[Abstract]
[Full Text]
-
Boyle, K. A., Traktman, P.
(2004). Members of a Novel Family of Mammalian Protein Kinases Complement the DNA-Negative Phenotype of a Vaccinia Virus ts Mutant Defective in the B1 Kinase. J. Virol.
78: 1992-2005
[Abstract]
[Full Text]
-
Broyles, S. S., Kremer, M., Knutson, B. A.
(2004). Antiviral Activity of Distamycin A against Vaccinia Virus Is the Result of Inhibition of Postreplicative mRNA Synthesis. J. Virol.
78: 2137-2141
[Abstract]
[Full Text]
-
Broyles, S. S.
(2003). Vaccinia virus transcription. J. Gen. Virol.
84: 2293-2303
[Abstract]
[Full Text]